Enter sample weight and dose/kg dose in the fields below for an automatic, customized calculation.
(Patient weight x Nplate® dose)
(Patient’s total dose ÷ 500 μg/mL)
Round volume to the nearest hundredth mL
Recommended Initial Dose
The recommended initial dose for Nplate® is 1 µg/kg based on actual body weight, administered once weekly as a subcutaneous injection. All dosing calculations should be based on actual body weight at initiation of treatment.
Use the actual body weight at initiation of therapy, then adjust the weekly dose of Nplate® by increments of 1 µg/kg until the patient achieves a platelet count ≥ 50 x 109/L. Assess the platelet count weekly until a stable platelet count (≥ 50 x 109/L for at least 4 weeks without dose adjustment) has been achieved. Obtain platelet counts monthly thereafter. Do not exceed a maximum weekly dose of 10 µg/kg.
Please consult the Product Monograph for complete dosing and administration information.
PrNplate® is indicated to increase the platelet levels in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP):
- who are nonsplenectomized and have had an inadequate response or are intolerant to corticosteroids and/or immunoglobulins;
- who are splenectomized and have had an inadequate response to splenectomy.
Nplate® has been used alone or in combination with other ITP therapies such as corticosteroids, azathioprine, or danazol.
Consult the Product Monograph at http://www.amgen.ca/Nplate_PM.pdf for important information on conditions of clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions and dosing that have not been discussed in this piece. The Product Monograph is also available by calling 1-866-502-6436.